Showing 1 - 20 results of 602 for search '(((( 50 ppm decrease ) OR ( 5 ppm decrease ))) OR ((( 20 mean decrease ) OR ( _ we decrease ))))', query time: 0.16s Refine Results
  1. 1
  2. 2

    LDL-C Targets in Secondary Prevention: How Low Should We Go? by Karim Bayoumy (3496688)

    Published 2019
    “…<h3>Abstract</h3><p dir="ltr">The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. …”
  3. 3
  4. 4

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit, Masania

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
    Get full text
    Get full text
    Get full text
    article
  5. 5

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit Masania (7164239)

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
  6. 6

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…However, questions related to its mechanism of interaction with the substrate, furimazine, as well as bioluminescence activity remain elusive. Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  7. 7
  8. 8

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…Additionally, we find that the N501Y mutant S1-RBD displays altered dynamics that likely aids in its enhanced interaction with ACE2. …”
  9. 9
  10. 10
  11. 11

    Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

    Published 2019
    “…Among the affected signaling networks were TGFβ1, SPP1, and ERK regulatory networks. Conclusions. We identified γ-secretase inhibitor (LY411575) as a potent regulator of osteoblastic differentiation of hBMSC that may be useful as a therapeutic option for treating conditions associated with ectopic bone formation.…”
  12. 12

    Performance evaluation of 3D-printed PLA composites doped with WE43 magnesium alloy for bone tissue engineering applications by Sumama Nuthana Kalva (17302906)

    Published 2025
    “…While a low Mg content (5 %) only slightly impacted the print quality and dimensions, higher Mg concentrations (10 % and 15 %) led to increased weight, rougher surfaces, dimensional shrinkage in height, and overall poorer formation quality. Adding WE43 alloy to PLA decreased the average pore sizes of the composites. …”
  13. 13
  14. 14
  15. 15

    Morphological changes in amblyopic eyes in choriocapillaris and Sattler’s layer in comparison to healthy eyes, and in retinal nerve fiber layer in comparison to fellow eyes through... by Masri, Oussama Samer

    Published 2021
    “…Purpose Establishing the reliability of a new method to check the mean retinal and choroidal reflectivity and using it to find retinal and choroid changes in amblyopia. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  16. 16

    The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3βY216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neu... by Wesal Habbab (17346961)

    Published 2019
    “…PP2A, GSK3β and Tau reside together in a complex, which facilitates their interaction and (dys)-function as has been reported for several neurological disorders. In this study we recorded maximum increase in total PP2A at 3 µM sodium selenate in a neuron cell line. …”
  17. 17

    Aortic valve function post-replacement of severe aortic stenosis by transcatheter procedure versus surgery: a systematic review and metanalysis by Charbel Abi Khalil (14150028)

    Published 2021
    “…TAVR was associated with 37% (95% CI [0.51–0.78) mean RR reduction of post-procedural PPM, a decrease that was not affected by the surgical risk at inclusion, neither by the transcatheter heart valve system. …”
  18. 18

    1787 evaluation of transperineal prostatic administration of a PSA-activasted protoxin (PRX302) in men with luts secondary to BPH by Elhilali, Mostafa

    Published 2010
    “…In the Phase I study, mean IPSS showed a decrease of 6.5 points (34%), mean QoL a decrease of 2 points (44%) and mean prostate volume a decrease of 5.5 cc (13%) at 12-months compared to screening. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  19. 19

    Role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma by Mansour, Ahmad M.

    Published 2014
    “…We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  20. 20

    Hydroxyurea Use in Lebanese Patients With [beta]-Thalassemia Intermedia by Taher, Ali

    Published 2006
    “…Seven patients with [beta]-thalassemia intermedia received oral HU (10-20 mg/kg/d); the mean duration of therapy was 17.4 (range 6-46) months. …”
    Get full text
    Get full text
    Get full text
    article